Market capitalization | $12.58b |
Enterprise Value | $25.53b |
P/E (TTM) P/E ratio | 15.96 |
EV/FCF (TTM) EV/FCF | 19.97 |
EV/Sales (TTM) EV/Sales | 2.04 |
P/S ratio (TTM) P/S ratio | 1.00 |
P/B ratio (TTM) P/B ratio | 21.29 |
Revenue growth (TTM) Revenue growth | 6.69% |
Revenue (TTM) Revenue | $12.52b |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
10 Analysts have issued a DaVita HealthCare Partners forecast:
10 Analysts have issued a DaVita HealthCare Partners forecast:
Jun '24 |
+/-
%
|
||
Revenue | 12,524 12,524 |
7%
7%
|
|
Gross Profit | 3,351 3,351 |
24%
24%
|
|
EBITDA | 2,589 2,589 |
29%
29%
|
EBIT (Operating Income) EBIT | 1,842 1,842 |
46%
46%
|
Net Profit | 860 860 |
89%
89%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services; and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.
Head office | United States |
CEO | Javier Rodriguez |
Employees | 70,000 |
Founded | 1994 |
Website | www.davita.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.